Sangamo Therapeutics (SGMO) Misses Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil rally pressures S&P, Nasdaq; Microsoft, Salesforce buoy Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Lumentum shares fall after hitting 52-week high
Sangamo Therapeutics Reports Third Quarter 2018 Financial Results
November 8, 2018 4:01 PM ESTRICHMOND, Calif., Nov. 8, 2018 /PRNewswire/ --Â Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported third quarter 2018 financial results and recent business highlights.
"I'm pleased with our continued execution toward our vision to transform Sangamo into the premier genomic medicines company," said Sandy Macrae, CEO of Sangamo.... More



